The new compounds will provide a “full time” protection of neurons against aging and degeneration. Continuous administration technologies, which are one of the core competencies of Axxonis Pharma AG, will additionally enable the concept of 24 hours protection. This is a completely new and innovative approach in radical scavenging therapy and in the therapy of neurological disorders induced by oxidative stress.

The new drugs in combination of non-invasive transdermal or minimal invasive (subcutaneous minipump) application methods will establish new potent neuroprotective therapies for patients suffering from Parkinson´s disease, Alzheimer´s disease, Huntington´s disease, Amyotrophic Lateral Sclerosis or Multiple System Atrophy or other neurological degenerative diseases induced by chemical radicals.

Axxonis Pharma AG has recently submitted Lisuride transdermal and subcutaneous drug products (Nenad®) for centralized EU procedure for continuous dopaminergic stimulation therapy of M. Parkinson and related disorders. Lisuride is known as a potent radical scavenger both in vitro and in vivo with strong antioxidant and neuroprotective effects in vulnerable CNS cell populations.

The new compounds which come from a joint research project, funded in part with financial means from the EU, between the Institute of Pharmacy (Prof. H.H. Pertz) of the Freie Universität Berlin, Germany, and Alfarma s.r.o., Cernosice, Czech Republic will extend significantly the portfolio of Axxonis Pharma AG and will substantiate long term growth.

Contact:

Dr. med. Antje Müller-Schubert
Clinical Research & Medical Relations
axxonis Pharma AG
Schöneberger Straße 15
D - 10963 Berlin

phone: +49 (0)30 - 269 34 29 14
fax: +49 (0)30 - 269 34 29 22
a.mueller-schubert@axxonis.com

To learn more about axxonis, please visit the website at:
www.axxonis.com
www.lisurid-cds.de